Compare Adaptive Biotechnologies Corp (ADPT) vs The Vita Coco Company Inc (COCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs The Vita Coco Company Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.05B), while The Vita Coco Company Inc trades at $64.43 (market cap $3.63B). The key difference: Adaptive Biotechnologies Corp and The Vita Coco Company Inc are close in size by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, The Vita Coco Company Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | COCO | |
|---|---|---|
Market Cap | $4.05B | $3.63B |
Sector | Health | Technology |
52-Week High | $25.45 | $84.02 |
52-Week Low | $12.15 | $32.37 |
Enterprise Value | $4.12B | $3.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
The Vita Coco Company (COCO) trades at $62.25, down 2.92% over 24 hours, with a bullish technical signal driven by oversold RSI readings and support near $62. Fundamentally, Q2 2026 earnings beat expectations with EPS of $0.82 versus $0.56 estimated, while revenue grew 28% year-over-year to $216 million. The company raised full-year 2026 guidance, reflecting strong demand and the Copra acquisition.
Outlook remains positive with 60% analyst buy ratings and an $80.67 consensus price target, implying ~30% upside. Key risks include margin pressure from rising costs and capacity constraints. Growth catalysts include international expansion and health-focused innovation in the beverage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About The Vita Coco Company Inc
The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →
